Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke
dc.contributor.author | Lemmerman, Luke R. | |
dc.contributor.author | Balch, Maria H.H. | |
dc.contributor.author | Moore, Jordan T. | |
dc.contributor.author | Alzate-Correa, Diego | |
dc.contributor.author | Rincon-Benavides, Maria A. | |
dc.contributor.author | Salazar-Puerta, Ana | |
dc.contributor.author | Gnyawali, Surya | |
dc.contributor.author | Harris, Hallie N. | |
dc.contributor.author | Lawrence, William | |
dc.contributor.author | Ortega-Pineda, Lilibeth | |
dc.contributor.author | Wilch, Lauren | |
dc.contributor.author | Risser, Ian B. | |
dc.contributor.author | Maxwell, Aidan J. | |
dc.contributor.author | Duarte-Sanmiguel, Silvia | |
dc.contributor.author | Dodd, Daniel | |
dc.contributor.author | Guio-Vega, Gina P. | |
dc.contributor.author | McTigue, Dana M. | |
dc.contributor.author | Arnold, W. David | |
dc.contributor.author | Nimjee, Shahid M. | |
dc.contributor.author | Sen, Chandan K. | |
dc.contributor.author | Khanna, Savita | |
dc.contributor.author | Rink, Cameron | |
dc.contributor.author | Higuita-Castro, Natalia | |
dc.contributor.author | Gallego-Perez, Daniel | |
dc.contributor.department | Surgery, School of Medicine | en_US |
dc.date.accessioned | 2022-06-23T12:41:31Z | |
dc.date.available | 2022-06-23T12:41:31Z | |
dc.date.issued | 2021-03-19 | |
dc.description.abstract | Ischemic stroke causes vascular and neuronal tissue deficiencies that could lead to substantial functional impairment and/or death. Although progenitor-based vasculogenic cell therapies have shown promise as a potential rescue strategy following ischemic stroke, current approaches face major hurdles. Here, we used fibroblasts nanotransfected with Etv2, Foxc2, and Fli1 (EFF) to drive reprogramming-based vasculogenesis, intracranially, as a potential therapy for ischemic stroke. Perfusion analyses suggest that intracranial delivery of EFF-nanotransfected fibroblasts led to a dose-dependent increase in perfusion 14 days after injection. MRI and behavioral tests revealed ~70% infarct resolution and up to ~90% motor recovery for mice treated with EFF-nanotransfected fibroblasts. Immunohistological analysis confirmed increases in vascularity and neuronal cellularity, as well as reduced glial scar formation in response to treatment with EFF-nanotransfected fibroblasts. Together, our results suggest that vasculogenic cell therapies based on nanotransfection-driven (i.e., nonviral) cellular reprogramming represent a promising strategy for the treatment of ischemic stroke. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Lemmerman LR, Balch MHH, Moore JT, et al. Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Sci Adv. 2021;7(12):eabd4735. Published 2021 Mar 19. doi:10.1126/sciadv.abd4735 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/29403 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Association for the Advancement of Science | en_US |
dc.relation.isversionof | 10.1126/sciadv.abd4735 | en_US |
dc.relation.journal | Science Advances | en_US |
dc.rights | Attribution-NonCommercial 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.source | PMC | en_US |
dc.subject | Cell differentiation | en_US |
dc.subject | Cellular reprogramming | en_US |
dc.subject | Fibroblasts | en_US |
dc.subject | Ischemic stroke | en_US |
dc.title | Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke | en_US |
dc.type | Article | en_US |